SG10202106375UA - Pharmaceutical compositions and use thereof - Google Patents

Pharmaceutical compositions and use thereof

Info

Publication number
SG10202106375UA
SG10202106375UA SG10202106375UA SG10202106375UA SG10202106375UA SG 10202106375U A SG10202106375U A SG 10202106375UA SG 10202106375U A SG10202106375U A SG 10202106375UA SG 10202106375U A SG10202106375U A SG 10202106375UA SG 10202106375U A SG10202106375U A SG 10202106375UA
Authority
SG
Singapore
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
SG10202106375UA
Other languages
English (en)
Inventor
Zhongzhou Liu
Chongdong Fu
Bin Shi
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of SG10202106375UA publication Critical patent/SG10202106375UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG10202106375UA 2015-05-25 2016-05-24 Pharmaceutical compositions and use thereof SG10202106375UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/079650 WO2016187767A1 (en) 2015-05-25 2015-05-25 Pharmaceutical compositions and use thereof

Publications (1)

Publication Number Publication Date
SG10202106375UA true SG10202106375UA (en) 2021-07-29

Family

ID=57392304

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202106375UA SG10202106375UA (en) 2015-05-25 2016-05-24 Pharmaceutical compositions and use thereof

Country Status (26)

Country Link
US (1) US20180153890A1 (zh)
EP (1) EP3302483B1 (zh)
JP (1) JP6878309B2 (zh)
KR (1) KR102573278B1 (zh)
CN (1) CN107613984B (zh)
AU (1) AU2016269304B2 (zh)
BR (1) BR112017024126B8 (zh)
CA (1) CA2985379C (zh)
CY (1) CY1123408T1 (zh)
DK (1) DK3302483T3 (zh)
ES (1) ES2796575T3 (zh)
HK (1) HK1245113A1 (zh)
HR (1) HRP20200935T1 (zh)
HU (1) HUE050697T2 (zh)
LT (1) LT3302483T (zh)
MX (1) MX2017014880A (zh)
MY (1) MY188169A (zh)
PH (1) PH12017502148A1 (zh)
PL (1) PL3302483T3 (zh)
PT (1) PT3302483T (zh)
RS (1) RS60355B1 (zh)
RU (1) RU2712187C2 (zh)
SG (1) SG10202106375UA (zh)
SI (1) SI3302483T1 (zh)
TW (1) TWI714588B (zh)
WO (2) WO2016187767A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541808A4 (en) * 2016-11-18 2020-07-22 Hutchison Medipharma Limited SOLID TUMOR TREATMENT PROCESS
CN111184698A (zh) * 2018-11-15 2020-05-22 和记黄埔医药（上海）有限公司 呋喹替尼制剂及其应用
US20220073642A1 (en) * 2020-09-07 2022-03-10 Hutchison Medipharma Limited Methods of using surufatinib in treating advanced pancreatic and extra-pancreatic neuroendocrine tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CA2559408C (en) * 2004-03-15 2014-05-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JO2860B1 (en) * 2009-05-07 2015-03-15 ايلي ليلي اند كومباني Phenylendazolyl compounds
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
CN102775385A (zh) * 2011-05-10 2012-11-14 湖南有色凯铂生物药业有限公司 N-取代苯基-n’-取代杂环脲类化合物及其作为抗癌药物的应用

Also Published As

Publication number Publication date
ES2796575T3 (es) 2020-11-27
CN107613984A (zh) 2018-01-19
PL3302483T3 (pl) 2020-11-02
KR102573278B1 (ko) 2023-09-01
EP3302483A4 (en) 2019-02-27
WO2016187767A1 (en) 2016-12-01
BR112017024126B1 (pt) 2023-04-11
JP6878309B2 (ja) 2021-05-26
PT3302483T (pt) 2020-06-16
RU2712187C2 (ru) 2020-01-24
NZ737544A (en) 2021-06-25
EP3302483A1 (en) 2018-04-11
RS60355B1 (sr) 2020-07-31
KR20180006422A (ko) 2018-01-17
HUE050697T2 (hu) 2020-12-28
SI3302483T1 (sl) 2020-07-31
MY188169A (en) 2021-11-24
LT3302483T (lt) 2020-06-25
CA2985379C (en) 2023-08-01
CA2985379A1 (en) 2016-12-01
CN107613984B (zh) 2021-04-30
HK1245113A1 (zh) 2018-08-24
HRP20200935T1 (hr) 2020-09-18
EP3302483B1 (en) 2020-04-15
BR112017024126A2 (pt) 2018-07-31
TW201641108A (zh) 2016-12-01
BR112017024126B8 (pt) 2023-05-09
AU2016269304B2 (en) 2021-04-15
CY1123408T1 (el) 2021-12-31
TWI714588B (zh) 2021-01-01
JP2018515587A (ja) 2018-06-14
RU2017139880A (ru) 2019-06-25
AU2016269304A1 (en) 2017-11-30
WO2016188399A1 (en) 2016-12-01
DK3302483T3 (da) 2020-06-15
US20180153890A1 (en) 2018-06-07
MX2017014880A (es) 2018-04-10
RU2017139880A3 (zh) 2019-10-03
PH12017502148A1 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
HK1251153A1 (zh) 一種藥物組合物及其應用
HK1249103B (zh) 多環氨甲醯基吡啶酮化合物及其藥物用途
IL258082B (en) History of benzaimidazole and pharmaceutical preparations containing them
IL252477A0 (en) 2-aminopyrimidine compound, pharmaceutical structure and its use
HK1252026A1 (zh) 藥物組合及其應用
HK1245086A1 (zh) 處方藥物組成及其製備和使用
HK1256674A1 (zh) 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途
ZA201703398B (en) Pharmaceutical composition and methods
HK1245085A1 (zh) 處方藥物組成及其製備和使用
IL263040A (en) Pharmaceutical composition comprising eteplirsen
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
HK1245113A1 (zh) 藥物組合物及其用途
IL254711B (en) History of diazepine-indole and medicinal preparations containing them
GB201519644D0 (en) Therapy and pharmaceutical composition
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
GB201522814D0 (en) Compositions and uses thereof
ZA201903341B (en) Pharmaceutical compositions and uses thereof
GB201713920D0 (en) Pharmaceutical compositions and uses thereof
GB201604810D0 (en) Pharmaceutical compositions and uses
GB201621959D0 (en) Compositions and their use
GB201602665D0 (en) Compositions and their use